Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 1Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 4Active not recruiting 4Recruiting 3Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Other hematologic neoplasm 1Breast 1

Conditions

Breast Neoplasms 109Carcinoma, Non-Small-Cell Lung 96Prostatic Neoplasms 60Multiple Myeloma 46Neoplasms 38Neoplasm Metastasis 33Ovarian Neoplasms 26Urinary Bladder Neoplasms 24Melanoma 24Lung Neoplasms 22Recurrence 21Parkinson Disease 4, Autosomal Dominant Lewy Body 21Leukemia, Lymphocytic, Chronic, B-Cell 21Colorectal Neoplasms 21Carcinoma, Renal Cell 20Leukemia, Myeloid, Acute 17Carcinoma, Hepatocellular 17Triple Negative Breast Neoplasms 16Lymphoma, Non-Hodgkin 16Stomach Neoplasms 15Nasopharyngeal Carcinoma 15Lymphoma 14Squamous Cell Carcinoma of Head and Neck 13Small Cell Lung Carcinoma 13Fallopian Tube Neoplasms 12Colonic Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11

Interventions

venetoclax 1taxane 1sargramostim 1rucaparib 1pembrolizumab 1olaparib 1Platinum 1Paclitaxel 1Observation 1Nivolumab 1Monatide (IMS 3015) 1Granulocyte-Macrophage Colony-Stimulating Factor 1Epirubicin 1Decitabine 1Cytarabine 1Cyclophosphamide 1Carboplatin 1Capecitabine 1Azacitidine 1Antimetabolites 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × Pathologic Complete Response × Clear all
NCT01844986 2025-12-10

SOLO-1

AstraZeneca

Phase 3 Active not recruiting
450 enrolled 18 charts 1 FDA
Gynecologic

Pathologic Complete Response, Ovarian Neoplasms

NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Lund University Hospital

Phase 3 Active not recruiting
325 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡